MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
22 sept. 2020 16h30 HE | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...